We have conducted the world’s largest clinical trials in diabetes, critical care and secondary prevention of stroke. Our flagship studies include ADVANCE, SAFE and PROGRESS. The results of these studies have driven change in treatment guidelines and patient care.
Largest clinical trial in diabetes – ADVANCE
11,140 patients, 20 countries, 216 centres
A factorial, randomised controlled trial study designed to determine the effects of intensive blood pressure lowering and glucose control on cardiovascular risks among type 2 diabetes patients. Covering both advanced economies in North America and Western Europe and emerging economies in Eastern Europe and Asia. ADVANCE had eighteen months for recruitment, an average of five years follow-up and achieved database lock in nine days. Results have been published in The Lancet and The New England Journal of Medicine.
Largest clinical trial in critical care medicine – SAFE
6,997 patients, 2 countries, 16 centres
A randomised controlled double-blind study comparing the effects of saline versus albumin on mortality in 6,997 patients, with up to 30 days of follow-up. Completed under budget and ahead of schedule, with results published in The New England Journal of Medicine.
Largest clinical trial for secondary prevention of stroke – PROGRESS
6,105 patients, 10 countries, 172 centres
A randomised, double-blind trial examining the effects of an ACE inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease. Results showed the treatment reduced risk of stroke by a quarter, and as a result such treatment is now recommended in international guidelines for treatment of hypertension, including the JNC7, WHO-ISH, European and Australian Guidelines, and in major guidelines for stroke management. Results have been published in The Lancet.